Published in Cancer Cell on December 01, 2011
Cancer genome landscapes. Science (2013) 25.33
CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood (2013) 2.22
Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells. Cell (2016) 2.10
Genetics of follicular lymphoma transformation. Cell Rep (2014) 1.70
IL-2-dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells. J Exp Med (2013) 1.68
What lessons can be learned from γδ T cell-based cancer immunotherapy trials? Cell Mol Immunol (2012) 1.54
Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell (2012) 1.54
Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget (2013) 1.44
Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP. PLoS One (2012) 1.42
Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med (2013) 1.26
The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification. Cancer J (2012) 1.26
MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma. Nat Immunol (2013) 1.17
Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia. Leukemia (2013) 1.14
The genetic basis of diffuse large B-cell lymphoma. Curr Opin Hematol (2013) 1.12
Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications. Clin Dev Immunol (2012) 1.03
Augmenting antitumor immune responses with epigenetic modifying agents. Front Immunol (2015) 0.98
Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas. Genome Biol (2014) 0.96
Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. Blood (2013) 0.96
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol Cancer (2015) 0.94
Targetome profiling, pathway analysis and genetic association study implicate miR-202 in lymphomagenesis. Cancer Epidemiol Biomarkers Prev (2013) 0.92
Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients. Blood (2014) 0.90
Genetic lesions in diffuse large B-cell lymphomas. Ann Oncol (2015) 0.89
Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma. Blood (2016) 0.88
Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks? Oncologist (2012) 0.88
The genetic landscape of diffuse large B-cell lymphoma. Semin Hematol (2015) 0.88
Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis. J Clin Oncol (2015) 0.87
Genetic similarity between cancers and comorbid Mendelian diseases identifies candidate driver genes. Nat Commun (2015) 0.86
Low GILT Expression is Associated with Poor Patient Survival in Diffuse Large B-Cell Lymphoma. Front Immunol (2013) 0.84
MutComFocal: an integrative approach to identifying recurrent and focal genomic alterations in tumor samples. BMC Syst Biol (2013) 0.82
Lymphoma: immune evasion strategies. Cancers (Basel) (2015) 0.82
Several immune escape patterns in non-Hodgkin's lymphomas. Oncoimmunology (2015) 0.82
Immune selection during tumor checkpoint inhibition therapy paves way for NK-cell "missing self" recognition. Immunogenetics (2017) 0.80
Adenovirus expressing β2-microglobulin recovers HLA class I expression and antitumor immunity by increasing T-cell recognition. Cancer Gene Ther (2014) 0.80
Large-scale microarray profiling reveals four stages of immune escape in non-Hodgkin lymphomas. Oncoimmunology (2016) 0.79
Promising personalized therapeutic options for diffuse large B-cell Lymphoma Subtypes with oncogene addictions. Clin Cancer Res (2012) 0.79
Impact of cytomegalovirus reactivation on relapse and survival in patients with acute leukemia who received allogeneic hematopoietic stem cell transplantation in first remission. Oncotarget (2016) 0.79
Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. Blood (2016) 0.79
Functional genomics lead to new therapies in follicular lymphoma. Ann N Y Acad Sci (2013) 0.79
Cancer immunotherapy: Strategies for personalization and combinatorial approaches. Mol Oncol (2015) 0.78
Cross-platform assessment of genomic imbalance confirms the clinical relevance of genomic complexity and reveals loci with potential pathogenic roles in diffuse large B-cell lymphoma. Leuk Lymphoma (2015) 0.78
Gene expression meta-analysis reveals immune response convergence on the IFNγ-STAT1-IRF1 axis and adaptive immune resistance mechanisms in lymphoma. Genome Med (2015) 0.77
Innate predisposition to immune escape in follicular lymphoma cells. Oncoimmunology (2012) 0.77
Donor KIR B Genotype Improves Progression-Free Survival of Non-Hodgkin Lymphoma Patients Receiving Unrelated Donor Transplantation. Biol Blood Marrow Transplant (2016) 0.77
Global gene expression changes of in vitro stimulated human transformed germinal centre B cells as surrogate for oncogenic pathway activation in individual aggressive B cell lymphomas. Cell Commun Signal (2012) 0.77
Targetless T cells in cancer immunotherapy. J Immunother Cancer (2016) 0.77
Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses. Oncotarget (2016) 0.77
Progress against follicular lymphoma. Curr Opin Hematol (2013) 0.76
Genomic Landscape of Primary Mediastinal B-Cell Lymphoma Cell Lines. PLoS One (2015) 0.76
RelA and RelB cross-talk and function in Epstein-Barr virus transformed B cells. Leukemia (2013) 0.76
TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses. Blood (2016) 0.76
Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies. Blood (2016) 0.76
Proteomics Based Identification of Proteins with Deregulated Expression in B Cell Lymphomas. PLoS One (2016) 0.76
In silico analyses reveal common cellular pathways affected by loss of heterozygosity (LOH) events in the lymphomagenesis of Non-Hodgkin's lymphoma (NHL). BMC Genomics (2014) 0.76
Lenalidomide in diffuse large B-cell lymphoma. Adv Hematol (2012) 0.76
Tumor-associated macrophages in diffuse large B-cell lymphoma. Haematologica (2015) 0.75
Synergistic activity of Card11 mutant and Bcl6 in the development of diffuse large B-cell lymphoma in a mouse model. Cancer Sci (2016) 0.75
Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica (2016) 0.75
Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors. Oncotarget (2016) 0.75
HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy? Oncoimmunology (2017) 0.75
Microenvironment abnormalities and lymphomagenesis: Immunological aspects. Semin Cancer Biol (2015) 0.75
Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies. J Immunol Res (2017) 0.75
Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine. Mod Pathol (2016) 0.75
CD58 mutations are common in Hodgkin lymphoma cell lines and loss of CD58 expression in tumor cells occurs in Hodgkin lymphoma patients who relapse. Genes Immun (2016) 0.75
Inhibition of STAT3 activity re-activates anti-tumor immunity but fails to restore the immunogenicity of tumor cells in a B-cell lymphoma model. Cancer Biol Ther (2014) 0.75
Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells. Leukemia (2016) 0.75
Genetic alterations in adult T-cell leukemia/lymphoma. Cancer Sci (2017) 0.75
Immune checkpoint blockade for hematologic malignancies: a review. Stem Cell Investig (2017) 0.75
Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer? Cold Spring Harb Mol Case Stud (2017) 0.75
Prediction of deleterious human alleles. Hum Mol Genet (2001) 21.00
A third-generation lentivirus vector with a conditional packaging system. J Virol (1998) 16.07
Structure of the human class I histocompatibility antigen, HLA-A2. Nature (1987) 14.54
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet (2010) 10.97
Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature (1986) 9.73
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature (2011) 9.71
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature (2010) 8.78
Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature (2009) 7.37
Oncogenically active MYD88 mutations in human lymphoma. Nature (2010) 7.34
Three distinct antigens associated with human T-lymphocyte-mediated cytolysis: LFA-1, LFA-2, and LFA-3. Proc Natl Acad Sci U S A (1982) 7.16
Immunological surveillance against altered self components by sensitised T lymphocytes in lymphocytic choriomeningitis. Nature (1974) 6.99
The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system. Annu Rev Immunol (1987) 6.94
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science (2008) 6.52
Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol (2008) 6.09
Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet (2011) 6.06
Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell (1985) 5.25
Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature (2011) 5.20
Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C, antigens. J Immunol (1979) 5.06
Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science (1993) 3.89
Aggressive lymphomas. N Engl J Med (2010) 3.86
Human tumor antigens recognized by T lymphocytes. J Exp Med (1996) 3.63
A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med (1997) 3.57
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature (2011) 3.22
Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med (2006) 3.14
BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell (2010) 2.73
The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol (2005) 2.42
Misfolded major histocompatibility complex class I heavy chains are translocated into the cytoplasm and degraded by the proteasome. Proc Natl Acad Sci U S A (1997) 2.39
The beta2-microglobulin mRNA in human Daudi cells has a mutated initiation codon but is still inducible by interferon. EMBO J (1983) 2.28
Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood (2005) 2.13
Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood (2002) 2.13
HLA-A- and HLA-B-specific monoclonal antibodies reactive with free heavy chains in western blots, in formalin-fixed, paraffin-embedded tissue sections and in cryo-immuno-electron microscopy. Int Immunol (1990) 2.12
Paired immunoglobulin-like receptors and their MHC class I recognition. Immunology (2005) 2.07
Anchoring mechanisms for LFA-3 cell adhesion glycoprotein at membrane surface. Nature (1987) 2.06
Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia (2007) 2.03
Regulation of MHC class I assembly and peptide binding. Annu Rev Cell Dev Biol (2008) 1.82
Structure of a heterophilic adhesion complex between the human CD2 and CD58 (LFA-3) counterreceptors. Cell (1999) 1.75
The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood (2002) 1.68
"Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer (2010) 1.43
Induction and blocking of cytolysis in CD2+, CD3- NK and CD2+, CD3+ cytotoxic T lymphocytes via CD2 50 KD sheep erythrocyte receptor. J Immunol (1986) 1.28
Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood (2000) 1.24
CD2/LFA-3 ligation induces phospholipase-C gamma 1 tyrosine phosphorylation and regulates CD3 signaling. J Immunol (1992) 1.22
Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med (2000) 1.19
beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J Clin Invest (1998) 1.17
Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer Res (1993) 1.05
Beta2-microglobulin aberrations in diffuse large B-cell lymphoma of the testis and the central nervous system. Int J Cancer (2003) 0.94
Ligand binding to the LFA-3 cell adhesion molecule induces IL-1 production by human thymic epithelial cells. J Immunol (1990) 0.86
Role of LFA-3, ICAM-1, and MHC class I on the sensitivity of human tumor cells to LAK cells. J Surg Res (1996) 0.80
Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest (2003) 16.67
Reverse engineering of regulatory networks in human B cells. Nat Genet (2005) 13.16
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med (2005) 12.18
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood (2004) 11.07
Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature (2009) 7.37
BRAF mutations in hairy-cell leukemia. N Engl J Med (2011) 7.05
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med (2007) 6.55
Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol (2008) 6.09
Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet (2011) 6.06
Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol (2006) 5.70
Genomic surveys by methylation-sensitive SNP analysis identify sequence-dependent allele-specific DNA methylation. Nat Genet (2008) 5.66
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature (2011) 5.20
The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature (2004) 5.06
The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell (2010) 4.71
Non-transcriptional control of DNA replication by c-Myc. Nature (2007) 4.55
Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell (2008) 4.43
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med (2011) 4.37
Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity (2004) 4.36
A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell (2007) 3.81
BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat Immunol (2005) 3.75
Transcriptional analysis of the B cell germinal center reaction. Proc Natl Acad Sci U S A (2003) 3.45
Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell (2005) 3.39
Akt-mediated regulation of autophagy and tumorigenesis through Beclin 1 phosphorylation. Science (2012) 3.24
Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med (2006) 3.14
Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma. Am J Gastroenterol (2013) 3.13
Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol (2013) 3.04
Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology (2004) 3.00
Acetylation inactivates the transcriptional repressor BCL6. Nat Genet (2002) 3.00
A systems biology approach to prediction of oncogenes and molecular perturbation targets in B-cell lymphomas. Mol Syst Biol (2008) 2.99
A human B-cell interactome identifies MYB and FOXM1 as master regulators of proliferation in germinal centers. Mol Syst Biol (2010) 2.92
Genome-wide identification of post-translational modulators of transcription factor activity in human B cells. Nat Biotechnol (2009) 2.79
AID is required for germinal center-derived lymphomagenesis. Nat Genet (2007) 2.79
IRF-4-binding protein inhibits interleukin-17 and interleukin-21 production by controlling the activity of IRF-4 transcription factor. Immunity (2008) 2.78
BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell (2010) 2.73
Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood (2011) 2.71
microRNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia. J Exp Med (2010) 2.68
Early-stage epigenetic modification during somatic cell reprogramming by Parp1 and Tet2. Nature (2012) 2.64
EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. Cell (2013) 2.63
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood (2012) 2.58
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood (2011) 2.44
The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood (2009) 2.36
Histamine deficiency promotes inflammation-associated carcinogenesis through reduced myeloid maturation and accumulation of CD11b+Ly6G+ immature myeloid cells. Nat Med (2010) 2.30
Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas. Blood (2012) 2.30
Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression. Genes Chromosomes Cancer (2008) 2.29
Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell (2012) 2.16
PKA-mediated phosphorylation regulates the function of activation-induced deaminase (AID) in B cells. Proc Natl Acad Sci U S A (2005) 2.13
Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood (2002) 2.13
Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood (2006) 2.06
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood (2011) 2.04
Reprogramming of CTLs into natural killer-like cells in celiac disease. J Exp Med (2006) 2.03
BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis. Adv Immunol (2010) 2.03
Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood (2003) 1.93
Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood (2002) 1.91
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med (2012) 1.90
The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry. Nat Immunol (2012) 1.90
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood (2012) 1.88
Risk of malignancy in patients with celiac disease. Am J Med (2003) 1.85
Werner syndrome protein limits MYC-induced cellular senescence. Genes Dev (2003) 1.84
Identification of the human mature B cell miRNome. Immunity (2009) 1.82
Tracking CD40 signaling during germinal center development. Blood (2004) 1.81
Prospective study of the role of duodenal bulb biopsies in the diagnosis of celiac disease. Gastrointest Endosc (2010) 1.79
Roles of BCL6 in normal and transformed germinal center B cells. Immunol Rev (2012) 1.78
Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas. Blood (2003) 1.74
Expression of the AID protein in normal and neoplastic B cells. Blood (2004) 1.73
Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol Cancer (2003) 1.73
Functional dissection of the chromosome 13q14 tumor-suppressor locus using transgenic mouse lines. Blood (2011) 1.72
tRNA-derived microRNA modulates proliferation and the DNA damage response and is down-regulated in B cell lymphoma. Proc Natl Acad Sci U S A (2013) 1.66
Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med (2012) 1.66